Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice: Demonstration of epitopes of oxidized low density lipoprotein in human plasma

Journal of Clinical Investigation

Volumn 98, Issue 3, 1996, Pages 800-814

  Palinski, Wulf ^a   Hörkkö, Sohvi ^a   Miller, Elizabeth ^a   Steinbrecher, Urs P ^c   Powell, Henry C ^b   Curtiss, Linda K ^d   Witztum, Joseph L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

atherosclerosis; autoantibodies; immune system; modified lipoproteins

Indexed keywords

APOLIPOPROTEIN E; ARACHIDONIC ACID; AUTOANTIBODY; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN; LYSINE; MALONALDEHYDE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNOGENICITY; LIPID PEROXIDATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0029957467     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118853     Document Type: Article

References (74)

1. Steinberg, D., S. Parthasarathy, T.E. Carew, J.C. Khoo, and J.L. Witztum. 1989. Beyond cholesterol. Modifications of low density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:915-924.
2. Witztum, J.L. 1994. The oxidation hypothesis of atherosclerosis. Lancet (N. Am. Ed.) 344:793-795.
3. Palinski, W., and J.L. Witztum. 1995. Oxidative stress and diabetes mellitus. In New Horizons in Diabetes Mellitus and Coronary Heart Disease. G.V.R. Born and C.D. Schwartz, editors. Current Science Group, London. 111-123.
4. Berliner, J.A., M. Navab, A.M. Fogelman, J.S. Frank, L.L. Demer, P.A. Edwards, A.D. Watson, and A.J. Lusis. 1995. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 91:2488-2496.
5. Witztum, J.L., U.P. Steinbrecher, M. Fisher, and A. Kesäniemi. 1983. Nonenzymatic glucosylation of homologous LDL and albumin render them immunogenic in the guinea-pig. Proc. Natl. Acad. Sci. USA. 80:2757-2761.
6. Palinski, W., M.E. Rosenfeld, S. Ylä-Herttuala, G.C. Gurtner, S.A. Socher, S. Butler, S. Parthasarathy, T.E. Carew, D. Steinberg, and J.L. Witztum. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86:1372-1376.
7. Palinski, W., S. Ylä-Herttuala, M.E. Rosenfeld, S. Butler, S.A. Socher, S. Parthasarathy, L.K. Curtiss, and J.L. Witztum. 1990. Antisera and monoclonal antibodies specific for epitopes generated during the oxidative modification of low density lipoprotein. Arteriosclerosis. 10:325-335.
8. Parums, D.V., D.L. Brown, and M.J. Mitchinson. 1990. Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch. Pathol. Lab. Med. 114:383-387.
9. Orekhov, A.N., V.V. Tertov, A.E. Kabakov, I.Y. Adamova, S.N. Pokrovsky, and V.N. Smirnov. 1991. Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler. Thromb. 11:316-326.
10. Palinski, W., V. Ord, A.S. Plump, J.L. Breslow, D. Steinberg, and J.L. Witztum. 1994. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14:605-616.
11. Salonen, J.T., S. Ylä-Herttuala, R. Yamamoto, S. Butler, H. Korpela, R. Salonen, K. Nyyssönen, W. Palinski, and J.L. Witztum. 1992. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet (N. Am. Ed.). 339:883-887.
12. Maggi, E., G. Finardi, M. Poli, P. Bollati, M. Filipponi, P.L. Stefano, G. Paolini, A. Grossi, P. Clot, E. Albano, et al. 1993. Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron. Artery Dis. 4:1119-1122.
13. Virella, G., I. Virella, R.B. Leman, M.B. Pryor, and M.F. Lopes-Virella. 1993. Antioxidized low density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Intl. J. Clin. Lab. Res. 23:95-101.
14. Branch, D.W., M.D. Mitchell, E. Miller, W. Palinski, and J.L. Witztum. 1994. Pre-eclampsia and serum antibodies to oxidised low density lipoprotein. Lancet (N. Am. Ed.) 343:645-646.
15. Armstrong, V.W., E. Wieland, F. Diedrich, A. Renner, W. Rath, H. Kreuzer, W. Kuhn, and M. Oellerich. 1994. Serum antibodies to oxidised low-density lipoprotein in pre-eclampsia and coronary heart disease [letter]. Lancet (N. Am. Ed.). 343:1570.
16. Maggi, E., R. Chiesa, G. Melissano, R. Castellano, D. Astore, A. Grossi, G. Finardi, and G. Bellomo. 1994. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler. Thromb. 14:1892-1899.
17. Puurunen, M., M. Mänttäri, V. Manninen, L. Tenkanen, G. Alfthan, C. Ehnholm, O. Vaarala, K. Aho, and T. Palosuo. 1994. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch. Intern. Med. 154:2605-2609.
18. Bellomo, G., E. Maggi, M. Poli, F.G. Agosta, P. Bollati, and G. Finardi. 1995. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes. 44:60-66.
19. Bergmark, C., R. Wu, U. de Faire, A.K. Lefvert, and J. Swedenborg. 1995. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 15: 441-445.
20. Heitzer, T., S. Ylä-Herttuala, J. Luoma, S. Kurz, T. Münzel, H. Just, M. Olschewski, and H. Drexler. 1996. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL. Circulation. 93:1346-1353.
21. Rosenfeld, M.E., W. Palinski, S. Ylä-Herttuala, S. Butler, and J.L. Witztum. 1990. Distribution of oxidation-specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 10:336-349.
22. Ylä-Herttuala, S., W. Palinski, S. Butler, S. Picard, D. Steinberg, and J.L. Witztum. 1994. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized low density lipoprotein. Arterioscler. Thromb. 14:32-40.
23. Palinski, W., R.K. Tangirala, E. Miller, S.G. Young, and J.L. Witztum. 1995. Increased autoantibody titers against epitopes of oxidized low density lipoprotein in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15:1569-1576.
24. Ohara, Y., T.E. Peterson, and D.G. Harrison. 1993. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91: 2546-2551.
25. Liao, F., A. Andalibi, F.C. deBeer, A.M. Fogelman, and A.J. Lusis. 1993. Genetic control of inflammatory gene induction and NF-κ B-like transcription factor activation in response to an atherogenic diet in mice. J. Clin. Invest. 91:2572-2579.
26. Palinski, W., E. Miller, and J.L. Witztum. 1995. Immunization of LDL receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA. 92:821-825.
27. Esterbauer, H., O. Quehenberger, and G. Jürgens. 1988. Oxidation of human low density lipoprotein with special attention to aldehydic lipid peroxidation products. In: Free Radicals: Methodology and Concepts. C. Rice-Evans and B. Halliwell, editors. Richelieu Press, London. 243-268.
28. Esterbauer, H., R.J. Schaur, and H. Zollner. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Rad. Biol. Chem. 11:81-128.
29. Esterbauer, H., J. Gebicki, H. Puhl, and G. Jürgens. 1992. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad. Biol. Med. 13:341-382.
30. Watson, A.D., M. Navab, S.Y. Hama, A. Sevanian, S.M. Prescott, D.M. Stafforini, T.M. McIntyre, B.N. La Du, A.M. Fogelman, and J.A. Berliner. 1995. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 95:774-782.
31. Heery, J.M., M. Kozak, D.M. Stafforini, D.A. Jones, G.A. Zimmerman, T.M. McIntyre, and S.M. Prescott. 1995. Oxidatively modified low density lipoprotein contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J. Clin. Invest. 96:2322-2330.
32. Hörkkö, S., E. Miller, E. Dudl, P.D. Reaven, N.J. Zvaifler, R. Terkeltaub, S.S. Pierangeli, L.K. Curtiss, W. Branch, W. Palinski, and J.L. Witztum. 1996. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J. Clin. Invest. 98:815-825.
33. Haberland, M.E., D. Fong, and L. Cheng. 1988. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science (Wash. DC). 241:215-241.
34. Ylä-Herttuala, S., W. Palinski, M.E. Rosenfeld, S. Parthasarathy, T.E. Carew, S. Butler, J.L. Witztum, and D. Steinberg. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1086-1095.
35. Boyd, H.C., A.M. Gown, G. Wolfbauer, and A. Chait. 1989. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am. J. Pathol. 135:815-826.
36. Holvoet, P., G. Perez, Z. Zhao, E. Brouwers, H. Bernar, and D. Collen. 1995. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J. Clin. Invest. 95:2611-2619.
37. Hammer, A., G. Kager, G. Dohr, H. Rabl, I. Ghassempur, and G. Jürgens. 1995. Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing serum lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15:704-713.
38. Malle, E., L. Hazell, R. Stocker, W. Sattler, H. Esterbauer, and G. Waeg. 1995. Immunologic detection and measurement of hypochlorite-modified LDL with specific monoclonal antibodies. Arterioscler. Thromb. Vasc. Biol. 15:982-989.
39. Daugherty, A., J.L. Dunn, D.L. Rateri, and J.W. Heinecke. 1994. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94:437-444.
40. Plump, A.S., J.D. Smith, T. Hayek, K. Aalto-Setälä, A. Walsh, J.G. Verstuyft, E.M. Rubin, and J.L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:343-353.
41. Zhang, S.H., R.L. Reddick, J.A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science (Wash. DC). 258:468-471.
42. Reddick, R.L., S.H. Zhang, and N. Maeda. 1994. Atherosclerosis in mice lacking apoE. Evaluation of lesional development and progression. Arterioscler. Thromb. 14:141-147.
43. Nakashima, Y., A.S. Plump, E.W. Raines, J.L. Breslow, and R. Ross. 1994. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the aortic tree. Arterioscler. Thromb. 14:133-140.
44. Ishibashi, S., M.S. Brown, J.L. Goldstein, R.D. Gerard, R.E. Hammer, and J. Herz. 1993. Hypereholesterolemia in low density lipoprotein receptor knockout mice and ils reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92:883-893.
45. Ishibashi, S., J.L. Goldstein, M.S. Brown, J. Herz, and D.K. Burns. 1994. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. Invest. 93:1885-1893.
46. Tangirala, R.K., E.M. Rubin, and W. Palinski. 1995. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apoprotein E-deficient mice. J. Lipid Res. 36:2320-2328.
47. Curtiss, L.K., and J.L. Witztum. 1983. A novel method for generating region specific monoclonal antibodies to modified proteins: application to the identification of human glucosylated low density lipoproteins. J. Clin. Invest. 72: 1427-1438.
48. Coppola, G., J. Underwood, G. Cartwright, and M.T.W. Hearn. 1989. High performance liquid chromatography of amino acids, peptides, and proteins. J. Chromatogr. 476:269-290.
49. Habeeb, A.F.S.A. 1966. Chemical evaluation of conformational differences in native and chemically modified proteins by trinitrobenzenesulfonic acid. Biochim. Biophys. Acta. 115:440-454.
50. Steinbrecher, U.P., J.L. Witztum, S. Parthasarathy, and D. Steinberg. 1987. Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis. 7:135-143.
51. Zhang, H., Y. Yang, and U.P. Steinbrecher. 1993. Structural requirements for the binding of modified proteins to the scavenger receptor of macrophages. J. Biol. Chem. 268:5535-5542.
52. Steinbrecher, U.P., M. Lougheed, W.C. Kwan, and M. Dirks. 1989. Recognition of oxidized LDL by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatly acid peroxidation. J. Biol. Chem. 264:15216-15233.
53. Gown, A.M., A.M. Vogel, D. Gordon, and P.L. Lu. 1985. A smooth muscle-specific monoclonal antibody recognizes smooth muscle actin isozymes. J. Cell Biol. 100:807-813.
54. Gown, A.M., T. Tsukada, and R. Ross. 1986. Human atherosclerosis: immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am. J. Pathol. 125:191-207.
55. Rosenfeld, M.E., J.C. Khoo, E. Miller, S. Parthasarathy, W. Palinski, and J.L. Witztum. 1991. Macrophage-derived loam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of LDL, and contain oxidation specific lipid-protein adducts. J. Clin. Invest. 87:90-99.
56. Hodis, H.N., D.M. Kramsch, P. Avogaro, G. Bittolo-Bon, G. Cazzolato, J. Hwang, H. Peterson, and A. Sevanian. 1994. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL). J. Lipid Res. 35:669-677.
57. Young, S.G., J.L. Witztum, D.C. Casal, L.K. Curtiss, and S. Bernstein. 1986. Conservation of the low density lipoprotein receptor-binding domain of apoprotein B: demonstration by a new monoclonal antibody, MB47. Arteriosclerosis. 6:178-188.
58. Young, S.G., R.S. Smith, D.M. Hogle, L.K. Curtiss, and J.L. Witztum. 1986. Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. Clin. Chem. 32:1484-1490.
59. Hoff, H.F., and J. O'Neil. 1993. Structural and functional changes in LDL after modification with both 4-hydroxynonenal and malondialdehyde. J. Lipid Res. 34:1209-1217.
60. Chisolm, G.M., G. Ma, K.C. Irwin, L.L. Martin, K.G. Gunderson, L.F. Linberg, D.W. Morel, and P.E. DiCorleto. 1994. 7 beta-hydroperoxycholest-5-en-3 beta-ol, a component of human atherosclerotic lesions, is the primary cytotoxin of oxidized human low density lipoprotein. Proc. Natl. Acad. Sci. USA. 91:11452-1156.
61. Coffey, M.D., R.A. Cole, S.M. Colles, and G.M. Chisolm. 1995. In vitro cell injury by oxidized low density lipoprotein involves lipid hydroperoxide-induced formation of alkoxyl, lipid, and peroxyl radicals. J. Clin. Invest. 96: 1866-1873.
62. Stemme, S., B. Faber, J. Holm, G. Bondjers, J.L. Witztum, and G.K. Hansson. 1995. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA. 92:3893-3897.
63. Huang, Y., J. Rönnelid, and J. Frostegard. 1995. Oxidized LDL induces enhanced antibody formation and MHC class II-dependent IFNγ production in lymphocytes from healthy individuals. Arterioscler. Thromb. Vasc. Biol. 15: 1577-1583.
64. Hansson, G.K., J. Holm, S. Holm, Z. Fotev, H.J. Hedric, and J. Fingerle. 1991. T lymphocytes inhibit the vascular response to injury. Proc. Natl. Acad. Sci. USA. 88:10530-10534.
65. Roselaar, S.E., G. Schonfeld, and A. Daugherty. 1995. Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J. Clin. Invest. 96:1389-1394.
66. Fyfe, A.I., J.-H. Qiao, and A.J. Lusis. 1994. Immune deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J. Clin. Invest. 94:2516-2520.
67. Itabe, H., E. Takeshima, H. Iwasaki, J. Kimura, Y. Yoshida, T. Imanaka, and T. Takano. 1994. A monoclonal antibody against oxidized lipoprotein recognizes loam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J. Biol. Chem. 269:15274-15279.
68. Itabe, H., H. Yamamoto, T. Imanaka, K. Shimamura, H. Uchiyama, J. Kimura, T. Sanaka, Y. Hata, and T. Takano. 1996. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J. Lipid Res. 37:45-53.
69. Houglum, K., M. Filip, J.L. Witztum, and M. Chojkier. 1990. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. J. Clin. Invest. 86:1991-1998.
70. Yan, S.D., X. Chen, A.M. Schmidt, J. Brett, G. Godman, Y.S. Zou, C.W. Scott, C. Caputo, T. Frappier, M.A. Smith, G. Perry, S.-H. Yen, and D. Stern. 1994. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc. Natl. Acad. Sci. USA. 91:7787-7791.
71. Newcombe, J., H. Li, and M.L. Cuzner. 1994. Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: implications for pathogenesis. Neuropathol. Appl. Neurobiol. 20:152-162.
72. Yan, S.D., A.M. Schmid, G.M. Anderson, J. Zhang, J. Brett, Y.S. Zou, D. Pinsky, and D. Stern. 1994. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol Chem. 269:9889-9897.
73. Neale, T.J., P.P. Ojha, M. Exner, H. Poczewski, B. Rüger, J.L. Witztum. P. Davis, and D. Kerjaschki. 1994. Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J. Clin. Invest. 94:1577-1584.
74. Witztum, J.L., and W. Palinski. 1996. Autoimmunity to oxidized lipoproteins. In: Immune Functions of the Vessel Wall. G.K. Hansson and P. Libby. editors. Harwood Academic Publishers GmbH., New York. In press.